Transformational Therapies Targeting Protein Degradation

Pioneering Tuneable Small-Molecule Degradation Platform

Dunad Therapeutics is focusing on the development of next-generation targeted protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tuneable mono-valent small molecules, unlocking new target space and allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

Our Science

Dunad’s unique small molecule platform induces targeted degradation of disease-causing proteins via direct modulation of the target protein’s surface topology. The Company’s novel molecular approach, based on mono-valent small molecules, is fully tuneable to be exquisitely selective for the target, and is underpinned by a target-class agnostic mechanism of action that is distinct from traditional mechanisms of targeted protein degradation.

Our Platform

The Company’s drug pipeline is powered by its expanding 4-pillar proprietary platform:

Proprietary Degradation Technology

Expanding the frontiers of our plug-and-play mono-valent degrader platform

Proprietary Screening Library

Accelerating Hit ID against novel targets

Proteomics Workflow

Unlocking previously inaccessible degradation targets via global and multi-dimensional profiling of the proteome

Bioinformatics Pipeline

Driving the best drug candidates through the development

Our Pipeline

Dunad is focusing on targets for which degradation is the optimal mechanism of action, and inhibition of the target’s activity alone is insufficient to elicit the maximum therapeutic effect.

While the unique MOA and compositions of our platform are expected to unlock access to the previously undruggable targets, our platform also enables development of orally bioavailable and CNS-accessible degrader therapeutics, together expanding the frontiers of protein degradation space.

Our Team

Dunad is continuing to expand its world-class scientific team with expertise across protein degradation, covalent therapeutics and proteomics, as well as it’s business leadership team.

Leadership Team

PEARL HUANG

President, CEO

Bio

PATRICK GUNNING

Founder CEO, Director

Bio

RUBEN TOMMASI

Chief R&D Officer

Bio

DIANA KRASKOUSKAYA

Founder, COO, Director

Bio

Scientific/Management Team

GRAHAM SIMPSON

Bio

GILES BROWN

Bio

JANE WILTON

Bio

MARTA CARRARA

Bio

MIRCO MENICONI

Bio

CONOR SCULLY

Bio

ALEX GUTTERIDGE

Bio

JEFFREY ST. DENIS

Bio

BARRY TEOBALD

Bio

MARGARET DANIEL

Bio

GRANT ANDREWS

Bio

MICHELLE HEATHCOTE

Bio

LAURA DONEHUE

Bio

Consultants

BERNHARD KUSTER

Bio

JEFF KEILLOR

Bio

MIKE MAZANETZ

Bio

JANE DANCER

Bio

Board members

PEARL HUANG

Bio

PATRICK GUNNING

Bio

ELIZABETH ROPER

Bio

OSKAR SLOTBOOM

Bio

Explore a career at Dunad

We’re hiring! Come work with our passionate team, pushing the boundaries of what small molecules are capable of.

Our Investors

Contact Us